Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) ...

Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

Between Casgevy's long-term potential and the company's innovative pipeline, CRISPR Therapeutics could eventually recover and ...

Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

The Boston Arts Academy Foundation closed its Building Our Future fundraising campaign, surpassing its $35 million goal, ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $452.16, moving +1.56% from the previous trading session. This change outpaced the S&P 500's 0.11% loss on the day. Meanwhile, the ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.